A prospective trial on the safety of long-term intensive plasmapheresis in donors

Vox Sanguinis

Volumn 88, Issue 3, 2005, Pages 189-195

  Bechtloff, S ^a   Tran My, B ^a   Haubelt, H ^a   Stelzer, G ^a   Anders, C ^a   Hellstern, Peter ^a  

^a Academic City Hospital   (Germany)

Author keywords

Blood coagulation; Cardiovascular risk; Intensive donor plasmapheresis; Safety

Indexed keywords

ALBUMIN; FERRITIN; HEMOGLOBIN; IMMUNOGLOBULIN G; IRON; PROTEIN; TRANSFERRIN;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD DONOR; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IRON METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAFETY; SOCIOECONOMICS;

ADULT; BLOOD COAGULATION; BLOOD DONORS; ERYTHROCYTES; FACTOR VIII; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN G; IRON; MALE; MIDDLE AGED; PLASMAPHERESIS; PROSPECTIVE STUDIES; RISK; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 17144429685     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2005.00632.x     Document Type: Article

References (18)

1. Kliman A, Carbone PP, Gaydos LA, Freireich EJ: Effects of intensive plasmapheresis on normal blood donors. Blood 1964; 23:647-656
2. Simson LR, Lien DM, Warner CL, Oberman HA: The long-term effects of repeated plasmapheresis. Am J Clin Pathol 1966; 45:367-372
3. Cohen MA, Oberman HA: Safety and long-term effects of plasmapheresis. Transfusion 1970; 10:58-66
4. Salvaggio J, Arquembourg P, Bickers J, Bice D: The effect of prolonged plasmapheresis on immunoglobulins, other serum proteins, delayed hypersensitivity and phytohemagglutinin-induced lymphocyte transformation. Int Arch Allergy 1971; 41:883-894
5. Shanbrom E, Lundak R, Walford RL: Long-term plasmapheresis: effects on specific plasma proteins. Transfusion 1972; 12:162-167
6. Friedman BA, Schork MA, Mocniak JL, Oberman HA: Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. Transfusion 1975; 15:467-472
7. Rodell MB: Collection of source plasma from remunerated donors. Dev Biol Stand 1993; 81:57-64
8. Rodell MB, Lee ML: Determination of reasons for cessation of participation in serial plasmapheresis programs. Transfusion 1999; 39:900-903
9. Tran-Mi Binh Storch H, Seidel K, Schulzki T, Haubelt H, Anders C, Nagel D, Siegler KE, Vogt A, Seiler D, Hellstern P: The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk factors. Vox Sang 2004; 86:189-197
10. German Federal Medical Association and the Paul Ehrlich Institute: [Guidelines to the Manufacture of Blood and Blood Components and to the Administration of Blood Products (Haemotherapy)]. Cologne, Deutscher Ärzte-Verlag, 2000
11. U.S. Food and Drugs Administration: Additional Standards for Human Blood and Blood Products. Code of Federal Regulations, Title 21, Volume 7, Subchapter F, part 640. Rochester, MD, USA. 2004.
12. Bier-Ulrich AM, Haubelt H, Anders C, Nagel D, Schneider S, Siegler KE, Seiler D, Hellstern P: The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo-controlled double-blind study. Transfusion 2003; 43:405-410
13. Council of Europe: Guide to the Preparation, Use and Quality Assurance of Blood Components, 10th edn. Strasbourg, Council of Europe Publishing, 2004
14. U.S. Food and Drugs Administration: Compliance Policy Guides Manual. Plasmapheresis - 48-hour period between plasmapheresis procedures CPG 7123.23. Chapter 2, Subchapter 256.100. Rochester, MD, USA. 2000.
15. Criqui MH, Golomb BA: Epidemiologic aspects of lipid abnormalities. Am J Med 1998; 105:485-575
16. Ridker PM: Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130:933-937
17. Lundsgaard-Hansen P: Intensive plasmapheresis as a risk factor for arteriosderotic cardiovascular disease? Vox Sang 1977; 33:1-4
18. Sagripanti A, Barsotti G: Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron 1995; 70:271-281